39results about How to "Monitor efficacy" patented technology

The present invention relates to capital equipment units, such as systems for providing medical treatment, that are associated with smart supplies. The smart supplies are tagged with data carriers which may encode such information as a unique ID for the supply or component, the identification of the supply or component, the identification of the source of the supply or component, the status of whether said supply or component has been previously used, the expiration date of the supply or component, and in the case where the supply or component contains drug, the purity levels of the drug and the concentration levels of the drug. The capital equipment units or their users then utilize the information to assure quality of any procedure run with the units, by way of improved pre-use checks, certification of the supplies for use, record keeping, inventory control, and charge capture.

Methods, systems, and computer program products for obtaining a sample in vivo and/or treating a subject include positioning an elongated transurethral catheter in the prostatic urethra of a subject, the catheter having a bladder anchoring balloon, at least one biosample entry port disposed axially away from the bladder anchoring balloon, and an axially extending biosample flow channel in fluid communication with the biosample entry port held internally in the catheter. The anchoring balloon is inflated to position the catheter so that the fluid entry port is proximate the prostatic urethra of the subject and prostatic fluid is suctioned from the prostatic urethra into the biosample entry port and into the biosample flow channel. The catheter can include a thermal treatment balloon and/or dilatation balloon and the suctioned sample can be obtained concurrently with, during, or proximate in time to the applied treatment. The catheter can be configured to allow urine to drain therethrough during the treatment/collection of the sample while keeping the urine isolated from the collected prostatic fluid sample.

The present invention provides assay methods for the determination of one or more anti-drug antibody (ADA) isotypes in a sample. As a non-limiting example, the assays of the present invention are particularly useful for determining different ADA isotypes in samples from ADA-positive patients receiving an anti-TNFα drug such as REMICADE™ (infliximab) or HUMIRA™ (adalimumab). The present invention also provides methods for optimizing therapy and/or reducing toxicity in subjects receiving TNFα inhibitors for the treatment of TNFα-mediated disease or disorders.

A set of brain data representing a time series of neurophysiologic activity acquired by spatially distributed sensors arranged to detect neural signaling of a brain (such as by the use of magnetoencephalography) is obtained. The set of brain data is processed to obtain a dynamic brain model based on a set of statistically-independent temporal measures, such as partial cross correlations, among groupings of different time series within the set of brain data. The dynamic brain model represents interactions between neural populations of the brain occurring close in time, such as with zero lag, for example. The dynamic brain model can be analyzed to obtain the neurophysiologic assessment of the brain. Data processing techniques may be used to assess structural or neurochemical brain pathologies.

Real time biofilm monitoring systems are provided. Said systems comprise single or multiple fiber-optic probes detecting wavelength-specific fluorescence from biomarkers of fouling organisms; a compact optoelectronic interface and data acquisition system interfaced with said probes, wherein said probe or probes are bifurcated and contain at least one excitation and at least one emission filter permitting the simultaneous resolution of multiple biomarkers.

A monoclonal antibody or fragment thereof, capable of specifically binding to at least one epitope of sH2a and/or being elicited by at least one epitope, and assays, kits, and methods of use thereof diagnosing liver disease or condition, detecting liver function and assessing the efficacy of therapy to a liver disease.

A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.

The present invention relates to a system device and method for monitoring infant oral motor kinetics (OMK), which can be used to assess the functional significance of the different sucking components, i.e., the plasticity of infant sucking skills in relation to their oral feeding performance, at a particular time, during the developmental period and/or during preventive or therapeutic intervention programs. It is a unique system and apparatus that provides a means to study the nonnutritive and/or nutritive sucking skills, i.e., the Suction and/or Expression components of sucking, of infants in the natural setting, i.e., during a normal feeding session. OMK sensors, tracked in real-time by the monitoring system, include miniature pressure transducers, or pressure sensitive pads, attached to the nipple for measuring intraoral pressure pulses during Suction, and for measuring compression/stripping pressure pulses during Expression; and a miniature flow sensor for measuring fluid flow rate, which can be integrated over time to determine the volume of milk removed (bolus) per suck. Other signals, such as respiration, swallowing, thermal, optical, and acoustic signals can be recorded and compared along with the instrumented-nipple signals, in an OMK monitoring system.

Systems and methods are disclosed for generating a therapeutic response predict or detecting a disease, by: using a genetic analyzer to generate genetic information; receiving into computer memory a training dataset comprising, for each of a plurality of individuals having a disease, (1) genetic information from the individual generated at first time point and (2) treatment response of the individual to one or more therapeutic interventions determined at a second, later, time point; and implementing a machine learning algorithm using the dataset to generate at least one computer implemented classification algorithm, wherein the classification algorithm, based on genetic information from a subject, predicts therapeutic response of the subject to a therapeutic intervention.

The present invention provides methods for detecting, measuring and quantitating the expression and activation states of signal transduction analytes in cells such as tumor cells. The invention also provides methods for selecting therapy, optimizing therapy, monitoring therapeutic efficacy, and/or detecting therapeutic resistance. Accordingly, the methods are useful for improving cancer therapy selection and disease monitoring.

Patient reported outcome (PRO) instruments are useful for collecting information from celiac disease patients, patients with gluten intolerance or gluten sensitivity, and patients on gluten free diets.

Proteonic cancer markers (PCMs) for breast, colon, liver and ovary were isolated, from the respective lysate of transformed cells, by differential centrifugation. Polyclonal antibodies were generated in mice against the (PCMs) for breast, colon, liver and ovary individually and combination thereof. Saliva from normal people was assayed by ELISA for antimixture of PCMs; breast, colon, liver and ovary cells individually. It was revealed that cancer antigen was detectable in saliva from normal people and the ELISA titer/100 μl ranged from 1:200 to 1:1600. Out of 32 normal salivas tested, ELISA titer was higher than 1:1000 in seven specimens. Those specimens were assayed by ELISA tests for individual PCM using anti-breast, anti-colon, anti-liver and anti-ovary. Each saliva specimen showed highest titer for one type of cancer antigen. Four saliva specimens showed high titers for breast PCM, two for colon one for liver. Only one saliva specimen showed high titer for ovary and colon PCMs. Thus, the invention further relates to the quantitative assessment of specific PCMs for breast, colon, liver and ovary in human saliva, by using antibodies against these markers individually.

Methods and assays for disease prognosis, detection and treatment monitoring are provided. The assays and methods measure functional immune responses to disease modified biomolecules (DMBs) that are characteristic of a disease of interest. Exemplary diseases of interest include rheumatoid arthritis (RA), for which citruUinated peptides or proteins (CPs), are characteristic DMBs.

Methods and reagents for determining treatment efficacy of a MALT1 inhibitor in a human subject are described. The method involves determining NF-κB nuclear translocation in stimulated PBMCs of a blood sample obtained from the subject. The method provides information for guiding treatment decisions for those subjects receiving a MALT1 inhibitor therapy, improves the accuracy of optimizing therapy, reduces toxicity, and/or monitors the efficacy of therapeutic treatment.

The measurement system 110 comprises a light source 120 configured and arranged for emitting a light beam via a polarization modulator 130 to a target position inside the skin 160, wherein the polarization modulator 130 is configured and arranged to simultaneously provide, in use, a first and a second region in a cross-section of the light beam in the target position, the first and the second region being distinct and having a corresponding first and second direction of polarization, the first and the second polarization direction being different from each other, and the measurement system also comprises a detection unit 150 to simultaneously detect a first and a second intensity of reflected light 145, the first intensity corresponding to light reflected from the first region of the light beam in the target position 160, and the second intensity corresponding to light reflected from the second region of the light beam in the target position 160, and the measurement system further comprises a processor being coupled to the detection unit 150 for determining a difference between the first and the second intensity.

The invention relates to open reading frame 2 (ORF-2) proteins of a swine hepatitis E virus and the use of these proteins as an antigen in diagnostic immunoassays and/or as immunogen or vaccine to protect against infection by hepatitis E.

The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.

The present invention relates to a composition comprising a plurality of cDNAs which are differentially expressed in prostate cancer and which may be used in their entirety or in part as to diagnose, to stage to treat or to monitor the treatment of a subject with prostate cancer.